Business Context and Reporting Period
This Form 8-K filing by Integer Holdings Corp (ITGR) is dated May 6, 2023, with the earliest event reported on May 8, 2023. The filing primarily addresses executive leadership changes and confirms the company's full-year 2023 financial guidance.
Key Financial Metrics and Guidance
The filing confirms the 2023 outlook previously issued on April 27, 2023. Key metrics for the full year 2023 (in millions, except per share amounts) are as follows:
| Metric | GAAP Range | GAAP YoY Change | Non-GAAP (Adjusted) Range | Non-GAAP YoY Change |
|---|---|---|---|---|
| Sales | $1,470 - $1,500 | 7% - 9% | N/A | N/A |
| Operating Income | $134 - $145 | 10% - 19% | $211 - $222 | 10% - 16% |
| EBITDA | N/A | N/A | $285 - $296 | 11% - 16% |
| Net Income | $71 - $81 | 8% - 24% | $134 - $144 | 4% - 11% |
| Diluted EPS | $2.11 - $2.41 | 8% - 23% | $4.00 - $4.30 | 3% - 11% |
| Cash Flow from Operations | $180 - $200 | 55% - 72% | N/A | N/A |
Supplemental Financial Information:
- Leverage Ratio: Expected to range from 2.5x to 3.5x (down from 3.5x in 2022).
- Capital Expenditures: Expected to range from $100 million to $120 million (up from $74 million in 2022).
- Adjusted Effective Tax Rate: Expected to range from 17.0% to 19.0% (up from 16.1% in 2022).
- Restructuring and Other Charges: Expected to range from $18 million to $23 million.
Material Changes and Executive Updates
Executive Departure and Appointment:
- Jason K. Garland departed as Executive Vice President and Chief Financial Officer effective May 8, 2023. His departure is not due to any disagreement regarding financial statements, internal controls, or accounting policies.
- Compensation: Mr. Garland is eligible to receive approximately $586,500 in separation benefits, consisting of his current annual salary plus medical insurance contributions.
- Interim CFO: Diron Smith, currently Vice President – Financial Planning & Analysis, was appointed Interim Chief Financial Officer effective May 8, 2023.
- Interim Compensation: Mr. Smith will receive an annual base salary of $321,000, short-term cash incentives (35% target), long-term incentive grants valued at $630,000, and standard executive benefits.
Search for Permanent CFO: The Company has commenced an internal and external search process to identify a permanent Chief Financial Officer.
Outlook, Risks, and Contingencies
Management Commentary: The company reaffirms its 2023 guidance, projecting growth in sales, operating income, and cash flow. The guidance excludes approximately $77 million in pre-tax items for Adjusted Operating Income and $81 million for Adjusted Net Income, primarily related to amortization, restructuring, and acquisition costs.
Risk Factors: The filing highlights several risks that could cause actual results to differ from forward-looking statements, including:
- Operational: Global supply chain issues, the Russia-Ukraine conflict, COVID-19 impacts, and dependence on a limited number of customers.
- Financial: Significant outstanding indebtedness, compliance with debt covenants, and access to capital markets.
- Regulatory: Compliance with European Union medical device regulations and other healthcare industry regulations.
- Strategic: Ability to successfully integrate acquisitions and respond to technological changes.
Investor Verification Checklist
- Verify the timeline and progress of the search for a permanent Chief Financial Officer.
- Monitor the company's ability to execute cost-saving measures to achieve the projected leverage ratio of 2.5x to 3.5x.
- Review the impact of the $100 million to $120 million capital expenditure plan on free cash flow.
- Assess the potential variability of the "Restructuring, acquisition and other charges" ($18M-$23M) and their effect on GAAP margins.
- Confirm the company's compliance with debt covenants given the significant indebtedness mentioned in risk factors.